Lexicon announces common stock offering, no amount given

Lexicon (LXRX) Pharmaceuticals announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock. Lexicon currently intends to use the net proceeds that it will receive from the proposed offering (i) to fund the continued research and development of its drug candidates and (ii) for working capital and other general corporate purposes. Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.